Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company

Read MoreHide Full Article

For Immediate Release

Chicago, IL – November 1, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Sony Group Corporation (SONY - Free Report) , American Express Company (AXP - Free Report) and The Southern Company (SO - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Alphabet, Eli Lilly and Sony

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet, Eli Lilly, and Sony. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Alphabet have outperformed the S&P 500 over the past year (+81.5% vs. +44%), with the better-than-expected Q3 results adding to the stock's momentum. The Zacks analyst believes that its focus on innovation, strategic acquisitions and Android OS will continue to generate strong cash flow.

A robust cloud division and expanding data centers continue to strengthen its presence in the cloud space. The company also continues to benefit from major updates in its search segment to enhance search results. Alphabet’s efforts to improve AI techniques and its focus on the home automation space should is expected to aid business growth in the long term.

(You can read the full research report on Alphabet here >>>)

Eli Lilly shares have gained +52.6% in the year to date period against the Zacks Large Cap Pharmaceuticals industry’s gain of +16.5%. The Zacks analyst believes that Lilly has been benefiting significantly higher demand for drugs like Trulicity, Taltz, and others. An intriguing pipeline for cancer, diabetes and Alzheimer's drugs is another tailwind.

The company recently submitted regulatory applications for tirzepatide and donanemab to be used in treatments for type II diabetes and early Alzheimer's disease, respectively. Both these candidates possess sales potential worth billions of dollars. Generic competition for several drugs, pricing pressure in the United States, and price cuts in certain international markets including China, Japan and Europe remain as major headwinds though.

(You can read the full research report on Eli Lilly here >>>)

Shares of Sony have gained +14.9% over the past six months against the Zacks Audio Video Production industry’s gain of +13.3%. The Zacks analyst believes that its Electronics Products & Solutions segment has been benefiting from an increase in sales of televisions and digital cameras.

Sony raised its outlook for the fiscal year ending Mar 31, 2022. The company has been witnessing a surge in Game & Network Services, Pictures, Music, and Electronics Products & Solutions segments sales. The continued increase in cost of goods sold is a major concern for the company though. It has a strong international presence with a chunk of its revenues stemming from emerging markets; this makes its susceptible to fluctuations in foreign currency exchange rates.

(You can read the full research report on Sony here >>>)

Other noteworthy reports we are featuring today include American Express and Southern Company.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                          

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Published in